RACTIGEN THERAPEUTICS has a total of 14 patent applications. Its first patent ever was published in 2019. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Republic of Korea. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are APTAHEM AB, DITESAN LTD and AAL SCIENT INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Republic of Korea | 2 | |
#4 | Australia | 1 | |
#5 | Canada | 1 | |
#6 | Israel | 1 | |
#7 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Sugars |
# | Name | Total Patents |
---|---|---|
#1 | Kang Moorim | 13 |
#2 | Li Longcheng | 13 |
#3 | Wu Jiancheng | 7 |
#4 | Place Robert F | 4 |
#5 | Kang Tao | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021052470A1 | Nucleic acid molecule for treating immune thrombocytopenia and application thereof | |
WO2021000928A1 | Oligomeric nucleic acid molecule activating atoh1 gene and use thereof | |
WO2020221309A1 | Oligomeric nucleic acid molecule, and application thereof in acute intermittent porphyria treatment | |
WO2020151726A1 | Oligonucleotides for skin care | |
WO2020135677A1 | Oligomeric nucleic acid molecule and application thereof | |
WO2020155534A1 | Oligonucleotide molecule and application thereof in tumor therapy | |
EP3778893A1 | Method for activating p21 gene expression | |
KR20200140377A | New small active RNA |